A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1637-1643

  Chai, Christy Y ^a   Deneve, Jeremiah L ^b,c   Beasley, Georgia M ^d   Marzban, Suroosh S ^b,c   Chen, Y Ann ^b   Rawal, Bhupendra ^b   Grobmyer, Stephen R ^e   Hochwald, Steven N ^e   Tyler, Douglas S ^d   Zager, Jonathan S ^b,c  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DACTINOMYCIN; MELPHALAN; SORAFENIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DRUG ADMINISTRATION ROUTE; FEMALE; FOLLOW UP; HUMAN; HYPERTHERMIC ISOLATED LIMB PERFUSION; INTERMETHOD COMPARISON; ISOLATED LIMB PERFUSION; LENGTH OF STAY; LIMB PERFUSION; MALE; MELANOMA; RECURRENT CANCER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LENGTH OF STAY; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84862554871     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2151-z     Document Type: Article

References (27)

1. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-32.
2. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. 1994;4(Suppl 1):45-50. (Pubitemid 24144674)
3. Muchmore JH, Wanebo HJ. Regional chemotherapy: overview. Surg Oncol Clin N Am. 2008;17:709-30.
4. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429-37. (Pubitemid 36833685)
5. Noorda EM, Takkenberg B, Vrouenraets BC, et al. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol. 2004;11:491-9. (Pubitemid 40486730)
6. Feldman AL, Alexander HR Jr, Bartlett DL, et al. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol. 1999;6:562-7. (Pubitemid 29428795)
7. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39-45. (Pubitemid 24039210)
8. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132:903-7. (Pubitemid 27344144)
9. Storm FK, Morton DL. Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am J Surg. 1985;150:32-5. (Pubitemid 15071744)
10. Hansson JA, Simert G, Vang J. The effect of regional perfusion treatment on recurrent melanoma of the extremities. Acta Chir Scand. 1977;143:33-9. (Pubitemid 8076205)
11. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551-61. (Pubitemid 19152772)
12. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer. 1993;29A:606-12. (Pubitemid 23036318)
13. Grunhagen DJ, van Etten B, Brunstein F, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol. 2005;12:609-15. (Pubitemid 41126090)
14. Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 1997;80:2084-90. (Pubitemid 27506021)
15. Klop WM, Vrouenraets BC, van Geel BN, et al. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg. 1996;182:467-72. (Pubitemid 26176477)
16. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009;115:1932-40.
17. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 2000;92:179-81. (Pubitemid 30099776)
18. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47:2150-7.
19. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-10. (Pubitemid 13147887)
20. Beasley GM, Tyler DS. Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma. Ann Surg Oncol. 2011;18:1814-8.
21. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706-15.
22. Lindner P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433-9. (Pubitemid 38528929)
23. Klaase JM, Kroon BB, van Geel AN, et al. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer. 1993;71:2990-4. (Pubitemid 23145528)
24. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003-13.
25. Ueno T, Ko SH, Grubbs E, et al. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188:532-7. (Pubitemid 39491100)
26. Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115:4766-74.
27. Beasley GM, Riboh JC, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011;29:1210-5.